Patents by Inventor David P. Hesson

David P. Hesson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190290635
    Abstract: The invention provides methods of treating brain cancer by providing an agent that inhibits an enzyme in a metabolic pathway in a cancer cell. In some methods of the invention, the agent is an inhibitor of dihydroorotate dehydrogenase. The invention also provides methods of determining a dosage of the therapeutic agent based on measured levels of a metabolite in the pathway.
    Type: Application
    Filed: March 26, 2019
    Publication date: September 26, 2019
    Inventors: Vikram S. Kumar, David P. Hesson
  • Publication number: 20190290892
    Abstract: The invention provides methods of determining a therapeutically effective dose of an agent that targets a metabolic pathway based on measured levels of a metabolite in the pathway. The methods, which may include providing the agent in a therapeutically effective dose, are useful for treating disorders, such as cancer, in a subject. The invention also provides methods for assessing the impact of a therapeutic agent on a tumor in a subject by monitoring, in real time, metabolism of a molecule in the tumor, oxygenation of the tumor, or both. The invention further provides devices that determine a therapeutically effective dose of an agent that targets a metabolic pathway based on measured levels of a metabolite in the pathway and notify a subject to administer the dose.
    Type: Application
    Filed: March 26, 2019
    Publication date: September 26, 2019
    Inventors: Vikram S. Kumar, David P. Hesson
  • Publication number: 20190290634
    Abstract: The invention provides therapeutic compositions that contain an inhibitor of dihydroorotate dehydrogenase (DHODH) and promote sustained elevation of dihydroorotate (DHO) levels in a patient. The compositions are useful for treating disorders associated with unregulated DHODH activity, such as acute myeloid leukemia. The invention also provides methods of determining therapeutically effective doses of compositions that contain a DHODH inhibitor. The invention further provides methods of synthesis of 2-(2?-halo-1-1?-biphenyl-4-yl)-quinoline carboxylic acids, which are useful as DHODH inhibitors.
    Type: Application
    Filed: March 26, 2019
    Publication date: September 26, 2019
    Inventors: Vikram S. Kumar, David P. Hesson
  • Publication number: 20190292154
    Abstract: The invention provides therapeutic compositions that contain an inhibitor of dihydroorotate dehydrogenase (DHODH) and promote sustained elevation of dihydroorotate (DHO) levels in a patient. The compositions are useful for treating disorders associated with unregulated DHODH activity, such as acute myeloid leukemia. The invention also provides methods of determining therapeutically effective doses of compositions that contain a DHODH inhibitor. The invention further provides methods of synthesis of 2-(2?-halo-1-1?-biphenyl-4-yl)-quinoline carboxylic acids, which are useful as DHODH inhibitors.
    Type: Application
    Filed: March 26, 2019
    Publication date: September 26, 2019
    Inventors: Vikram S. Kumar, David P. Hesson, Ping Huang, Mo Jia, Xianjun You
  • Patent number: 6689756
    Abstract: Provided is, among other things, a method of treating in an animal infection or neoplasm of cerebrospinal tissue characterized by a risk of death, the method comprising: (a) injecting a physiologically acceptable fluid for cerebrospinal perfusion into a first catheter into the cerebrospinal pathway, which fluid for cerebrospinal perfusion has an therapeutically effective amount an agent, the agent selected for effectiveness against the infection as identified or diagnosed; (b) withdrawing fluid at a second catheter into the cerebrospinal pathway to create a flow and flow pathway between the first and second catheters; and (c) maintaining the flow for a period of time adapted to perfuse at least 1 CSF volume.
    Type: Grant
    Filed: March 4, 2002
    Date of Patent: February 10, 2004
    Assignee: Integra LifeSciences Corporation
    Inventors: David P. Hesson, Timothy J. Pelura, Glen D. Frazer
  • Publication number: 20030163181
    Abstract: Provided, among other things, is a method of treating, in an animal, an injury that is stroke, traumatic brain injury including traumatic surgical brain injury, brain hemorrhage other than stroke, spinal cord traumatic injury including spinal cord surgical trauma, infection, ischemia caused by surgical intervention, CNS injury caused by cardiac arrest, encephalitis or encephalomyelitis not due to infection, comprising: (a) creating a flow pathway, with an instillation catheter and an effluent catheter, that provides liquid flow in the vicinity of the injury; (b) instilling into the flow pathway an cerebrospinal perfusion fluid having a temperature from (i) 4° C. as a lower temperature to (ii) 4° C. below normal temperature of the animal; and (c) maintaining perfusion through the flow pathway for at least 12 hours of the cerebrospinal perfusion fluid having a temperature, at the point of instillation, from (i) 4° C. as a lower temperature to (ii) 4° C. below normal temperature of the animal.
    Type: Application
    Filed: December 9, 2002
    Publication date: August 28, 2003
    Applicant: Neuron Therapeutics, Inc.
    Inventors: Glenn D. Frazer, David P. Hesson, Timothy J. Pelura, James C. Barnitz
  • Publication number: 20030135196
    Abstract: Subarachnoid hemorrhage is treated by circulating a synthetic cerebrospinal fluid containing an emulsifying agent in the cerebrospinal fluid pathway in the vicinity of hemorrhage. The emulsifying agent scavenges blood products and circulation of the synthetic cerebrospinal fluid clears the blood products form the subarachnoid space to reduce cerebral vasospasm.
    Type: Application
    Filed: August 28, 2002
    Publication date: July 17, 2003
    Applicant: Neuron Therapeutics, Inc.
    Inventors: David P. Hesson, Glen D. Frazer, Timothy J. Pelura, Barbara L. Powers, Bruce Shook
  • Publication number: 20030060421
    Abstract: Provided, among other things, is a kit providing pre-measured amounts of components to form a fluorocarbon nutrient emulsion capable of carrying oxygen to living tissue, the kit comprising: constituent solutions, emulsions or particle compositions, which are the constituent compositions, containing pre-measured amounts of components for making the fluorocarbon nutrient emulsion, the constituent compositions comprising: poly-fluorinated, oxygen-carrying compound; a physiologically acceptable emulsifying agent effective to emulsify the polymer; a nutrient-providing effective amount of carbohydrate; nutrient-providing effective amounts of amino acids or amino acid precursors; an oncotic agent in amount effective to provide, in conjunction with the other components of the solution, a physiologically acceptable oncotic pressure; and sufficient salts and buffering agents to provide a physiological osmotic pressure and physiologically appropriate concentrations of potassium and sodium ions; wherein constituent compo
    Type: Application
    Filed: July 19, 2001
    Publication date: March 27, 2003
    Applicant: Neuron Therapeutics, Inc.
    Inventors: David P. Hesson, Glenn David Frazer, Timothy J. Pelura
  • Publication number: 20030022879
    Abstract: Provided is, among other things, a method of treating in an animal infection or neoplasm of cerebrospinal tissue characterized by a risk of death, the method comprising: (a) injecting a physiologically acceptable fluid for cerebrospinal perfusion into a first catheter into the cerebrospinal pathway, which fluid for cerebrospinal perfusion has an therapeutically effective amount an agent, the agent selected for effectiveness against the infection as identified or diagnosed; (b) withdrawing fluid at a second catheter into the cerebrospinal pathway to create a flow and flow pathway between the first and second catheters; and (c) maintaining the flow for a period of time adapted to perfuse at least 1 CSF volume.
    Type: Application
    Filed: March 4, 2002
    Publication date: January 30, 2003
    Inventors: David P. Hesson, Timothy J. Pelura, Glen D. Frazer
  • Publication number: 20020193335
    Abstract: Provided is a method of delivering to neurological tissue a transforming composition or a transformed cell, the method comprising: a. injecting a physiologically acceptable cerebrospinal perfusion fluid into a first catheter into the cerebrospinal pathway, which cerebrospinal perfusion fluid has a gene therapy effective amount of gene therapy agent or transformed cells; b. withdrawing fluid at a second catheter into the cerebrospinal pathway to create a flow and flow pathway between the first and second catheters; and c. maintaining the flow for a period of time adapted to perfuse at least 1 CSF volume.
    Type: Application
    Filed: March 4, 2002
    Publication date: December 19, 2002
    Inventors: David P. Hesson, Glen D. Frazer, Bruce Shook
  • Publication number: 20020193285
    Abstract: Provided is a method of treating in an animal that has suffered damage to cerebrospinal tissue or that has an indication creating a risk of damage to cerebrospinal tissue, the method comprising: a. injecting a physiologically acceptable cerebrospinal perfusion fluid into a first catheter into the cerebrospinal pathway, which cerebrospinal perfusion fluid has a neuroprotecting effective amount of a neuroprotectant; b. withdrawing fluid at a second catheter into the cerebrospinal pathway to create a flow and flow pathway between the first and second catheters; and c. maintaining the flow for a period of time adapted to perfuse an affected tissue.
    Type: Application
    Filed: March 4, 2002
    Publication date: December 19, 2002
    Inventors: David P. Hesson, Glen D. Frazer, Douglas Ross
  • Patent number: 5032597
    Abstract: Phenylquinolinecarboxylic acids and derivatives thereof, such as 2-(2'-fluoro-1,1'-biphenyl-4-yl)-6-fluoro-3-methyl-4-quinolinecarboxylic acid, or a sodium or potassium salt thereof, are useful as tumor inhibiting agents.
    Type: Grant
    Filed: March 26, 1987
    Date of Patent: July 16, 1991
    Assignee: Du Pont Merck Pharmaceutical
    Inventor: David P. Hesson
  • Patent number: 4680299
    Abstract: Phenylquinolinecarboxylic acids and derivatives thereof, such as 2-(2'-fluoro-1,1'-biphenyl-4-yl)-6-fluoro-3-methyl-4-quinolinecarboxylic acid, or a sodium or potassium salt thereof, are useful as tumor inhibiting agents.
    Type: Grant
    Filed: April 26, 1985
    Date of Patent: July 14, 1987
    Assignee: E.I. Du Pont de Nemours and Company
    Inventor: David P. Hesson
  • Patent number: 4639454
    Abstract: Phenylquinazolinecarboxylic acids and derivatives thereof, such as 2-(1,1'-biphenyl-4-yl)-6-fluoro-4-quinazoline carboxylic acid, sodium salt and 2-(1,1'-biphenyl-4-yl)-4-quinazoline carboxylic acid, sodium salt, are useful as tumor-inhibiting agents.
    Type: Grant
    Filed: January 17, 1985
    Date of Patent: January 27, 1987
    Assignee: E. I. Du Pont de Nemours and Company
    Inventor: David P. Hesson